On September 27, 2022 Alentis Therapeutics ("Alentis" or "the Company"), the biotechnology company developing breakthrough treatments for organ fibrosis and fibrotic-associated cancers, reported the Swiss Innovation Agency, Innosuisse, will co-fund a research collaboration with the FHNW School of Life Sciences to accelerate the discovery of Claudin-1-associated biomarkers for fibrosis (Press release, Alentis Therapeutics, SEP 27, 2022, View Source [SID1234621439]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Claudin-1 (CLDN1) is a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of organ fibrosis and fibrotic tumors. Alentis’ lead therapeutic candidate, ALE.F02, is currently in Phase 1 clinical studies for the treatment of advanced kidney, liver and lung fibrosis which are expected to read out in Q1 2023. The Company is also developing ALE.C04 for solid tumors that is currently in pre-clinical development.
Alentis Therapeutics will partner with the School of Life Sciences to test anti-CLDN1 antibodies in established 3D-multicellular liver co-culture systems, developed and validated by Prof. Dr. Laura Suter-Dick’s lab at the FHNW Campus Muttenz, Basel-Landschaft, Switzerland, and published recently in the International Journal of Molecular Science. The goal is to identify translational biomarkers of CLDN1 target engagement that be deployed in future Alentis trials. The total project cost of CHF 720,000 will be supported by the grant from Innosuisse and contributions from Alentis Therapeutics.
Dr. Geoffrey Teixeira, Head of Fibrosis at Alentis Therapeutics, commented: "With the support of Innosuisse, we look forward to continuing our close collaboration with Prof. Dr. Laura Suter-Dick’s group to provide further validation and monitoring of the therapeutic effect of CLDN1 inhibition in fibrotic disorders. This is another important step in our goal to develop breakthrough treatments for organ fibrosis and fibrotic-associated cancers."
Prof. Dr. Laura Suter-Dick, Professor of Cell Biology and In Vitro Toxicology at FHNW, added: "We are grateful to Innosuisse for its support in promoting science-based innovation in Switzerland. Through our continued collaboration with the Alentis team, we aim to identify translational biomarkers of CLDN1 target engagement for use in future clinical trials."